Quick Answer
NeuroSense Therapeutics Ltd. reported Research And Development Expense of $6.23 million for the year ending 2025.
- NeuroSense Therapeutics Ltd. showed an increase of +9.3% in Research And Development Expense from 2024 to 2025.
- This data is from NeuroSense Therapeutics Ltd.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), NeuroSense Therapeutics Ltd.'s Research And Development Expense has grown by 11.5%.
- Historical annual values: Fiscal year 2025: $6.23 million | Fiscal year 2024: $5.70 million | Fiscal year 2023: $7.27 million | Fiscal year 2022: $5.59 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: